Acquired by Nordic Capital in 2008, ConvaTec is a developer and marketer of innovative medical technologies sold in over 100 countries. In late 2016, ConvaTec was listed on the main market of the London Stock Exchange and subsequently included in the FTSE 100 index. The listing represented the largest European healthcare IPO in more than 20 years and the largest MedTech IPO globally in more than 10 years.
ConvaTec is a global medical products and technologies company, focused largely on chronic care devices in the areas of advanced wound care, ostomy care, continence& critical care and infusion devices. The company’s products provide clinical and economic benefits including infection prevention and improved patient outcomes in addition to reduced cost of care. ConvaTec has over 8,500 employees and 9 manufacturing sites globally.
"Improving the lives of the people we touch" - ConvaTec
Why Nordic Capital invested in this business:
"Not only does ConvaTec operate in a growing market, there is potential to optimise the cost base and drive further growth through new product launches" - Patrick Knechtli, SL Capital
"ConvaTec is a strong endorsement of Nordic Capital's expertise in the healthcare sector as they have engineered a complex spin-out from a large healthcare conglomerate, grown the business through multiple channels and facilitated a successful IPO in London" – Patrick Knechtli, SL Capital